Blood Banking Reagents: Overview and Applications

Overview of Blood Banking Reagents

• Goal of Reagents: The primary objective of blood banking reagents is to ensure safe and compatible transfusions by accurately identifying antigens on red blood cells (RBCs) and antibodies in serum or plasma.

• Key Performance Characteristics:

  • Specificity: The ability of a reagent to recognize a specific antigenic determinant (epitope) and its corresponding antibody. It ensures that the antibody reacts only with its intended antigen.

  • Potency: Refers to the strength of the reaction. Commercial reagents must meet minimum standards established by regulatory bodies.

Regulatory Oversight and Quality Control

• Licensing: Commercial blood banking reagents are licensed by the Center for Biologics Evaluation and Research (CBER), which is a branch of the Food and Drug Administration (FDA).

• Regulations: The criteria for these reagents are codified in the Code of Federal Regulations.

• Quality Control (QC) Program:

  • Frequency: QC must be performed daily on commercial cells and antisera to ensure they meet performance criteria.

  • Components of QC:

    • A clear statement of the criteria for acceptable reagent performance.

    • Comprehensive documentation of reagent use.

    • Specified corrective actions to be taken if a reagent fails to perform as expected.

Types of Commercial Antibody Reagents

Monoclonal Antibodies

• Production: Secreted by a single clone of antibody-producing B cells using hybridoma technology.

• Composition: Contains only one immunoglobulin class (either $IgG$ or $IgM$).

• Specificity: Features unique specificity for a single particular epitope.

• Examples: Anti-A, anti-c, and anti-IgG antibodies.

Polyclonal Antibodies

• Production: Secreted by several different clones of antibody-producing B cells.

• Composition: A mixture of $IgM$ and $IgG$ antibodies.

• Specificity: A mixture of antibodies that may be directed at different epitopes of the same antigen (recognizes multiple epitopes).

• Example: Antihuman globulin (AHG).

ABO and D Typing Reagents

ABO Grouping Reagents

• Composition: Murine monoclonal antibodies. They are formulated to provide strong reactions (typically $3+$ to $4+$).

• Anti-A: Directed toward the A antigen; contains blue dye for identification.

• Anti-B: Directed toward the B antigen; contains yellow dye for identification.

• Anti-A,B: A blend of anti-A and anti-B clones; the reagent is clear.

• Applications: Used on patient red cells to determine the ABO blood type. This process is known as ABO grouping, forward grouping, front typing, or ABO red cell testing.

D Antigen Typing (Rh System)

• D Antigen Significance: The D antigen is the most immunogenic and important antigen in the Rh blood group system for routine blood banking.

• Requirement: The AABB requires all blood samples to be typed for the D antigen.

• Anti-D Reagents:

  • High-Protein Reagents: Contain polyclonal antibodies in approximately $20\%$ bovine albumin. They promote false-positive agglutination and require a separate reagent control.

  • Low-Protein Reagents: Contain monoclonal antibodies ($IgM$) or monoclonal/polyclonal blends in approximately $6\%$ bovine albumin. These have largely replaced high-protein reagents.

  • Specific Formulations:

    • Monoclonal-Polyclonal Blend: $IgM$ anti-D from human-murine heterohybridoma mixed with polyclonal $IgG$ anti-D.

    • Monoclonal Blend: A mix of $IgM$ and $IgG$ from human-murine heterohybridomas.

    • Monoclonal: $IgM$ from a single clone.

Low-Protein Reagent Control

• Purpose: Ensures that typing results are correct and that agglutination is not caused by the medium itself.

• Expected Result: Controls should show no agglutination (negative).

• Interferences: False-positive agglutination can result from strong cold autoantibodies or protein abnormalities.

• Usage Criteria:

  • A separate control is mandatory if the patient\'s RBCs agglutinate with all ABO antisera.

  • A separate control is not required if any of the ABO low-protein reagents yield a negative result.

Reagent Red Blood Cells

A1 and B Red Cells

• Purpose: Used for reverse group typing (ABO serum testing). This involves testing patient plasma or serum against known red cells to detect ABO antibodies and confirm the forward typing.

• Reaction Level: Formulated to give a strong reaction ($3+$ to $4+$).

• Phase: Testing is performed in the immediate-spin (IS) phase.

Screening Cells

• Purpose: Used in the antibody screen (detection) test to identify "unexpected" antibodies.

• Packaging: Available in sets of $2$ or $3$ vials.

• Donor Source:

  • Pooled cells: Used only for donor testing.

  • Single-donor vials: Mandatory for pre-transfusion testing (recipients). These tend to give stronger reactions.

• FDA Requirements: Screening cells must express antigens for: $D$, $C$, $E$, $c$, $e$, $M$, $N$, $S$, $s$, $P_1$, $Le^a$, $Le^b$, $K$, $k$, $Fy^a$, $Fy^b$, $Jk^a$, and $Jk^b$.

• Antigram: Each lot comes with an antigram documenting the antigenic profile of each vial.

Panel Cells

• Purpose: Used for identifying antibodies (antibody panel) after a positive screening test.

• Configuration: Typically obtained in sets of $10$ or more vials, each with a detailed antigram.

Antiglobulin Testing

Principle

• Commercial antibodies (AHG) specific to human globulins (antibodies or complement) are used to bridge the gap between antibody-coated RBCs, resulting in visible agglutination.

• Target Globulins: $IgG$ (anti-IgG) and/or Complement (anti-C3d, anti-C3b).

Direct Antiglobulin Test (DAT)

• Definition: Detects $IgG$ or complement bound to red cells in vivo (inside the body).

• Clinical Indicators for Positive DAT:

  • Transfusion Reaction: Caused by donor cells coated with recipient (patient) antibody ($IgG$).

  • Hemolytic Disease of the Fetus and Newborn (HDFN): Caused by fetal red cells coated with maternal $IgG$ that crossed the placenta.

  • Autoimmune Hemolytic Anemia (AIHA): Patient red cells coated with patient autoantibody ($IgG$ or $C3$).

  • Drug-Related Mechanisms: $IgG$-drug complexes attached to cells, forming immune complexes.

Indirect Antiglobulin Test (IAT)

• Definition: Detects $IgG$ or complement bound to red cells in vitro (performed in the lab environment).

Antiglobulin Reagents

• Polyspecific AHG:

  • Contains both anti-IgG and anti-C3d antibodies.

  • Agglutination indicates the cells are coated with either $IgG$, complement, or both. If positive, a differential DAT is required to determine which is present.

• Monospecific AHG:

  • Anti-IgG: Combines with human gamma chains.

  • Anti-C3b/C3d: Specifically detects complement proteins resulting from the activation of the classical pathway (associated with intravascular and extravascular hemolysis).

Antiglobulin Control Cells

• IgG Sensitized Cells (Check Cells):

  • Required by AABB to confirm valid negative AHG results.

  • Type O RBCs prepared with $IgG$ antibodies attached. When added to a negative AHG test, agglutination must occur.

  • Causes of False-Negatives: Failure to add AHG, failure of AHG to react, or inadequate washing of RBCs.

• Complement Control Cells: Type O RBCs prepared with $C3d$ antibodies attached. Used to confirm negative anti-C3 tests.

Potentiators and Enzymes

Enzyme Effects on Antigens

• Antigens Denatured: $Fy^a$, $Fy^b$, $M$, $N$, $S$, $s$, $Xg^a$, $Ch$, $Rg$, and $JMH$.

• Antigens Resistant or Enhanced: $ABO$, $Rh$, $Kidd$, $P_1$, $Lewis$, $Lutheran$, $Sd^a$, and $I$.

• Ficin Control: Glycine soja is used as a control.

Lectins

Lectins are plant extracts that react with specific RBC antigens:

• Dolichos biflorus: Specific for the $A_1$ phenotype.

• Ulex europaeus: Specific for the H antigen.

• Vicia graminea: Specific for the N antigen.

• Iberis amara: Specific for the M antigen.

Advanced Testing Technologies

Gel Column Agglutination Technology

• Principle: Uses dextran acrylamide gel particles to trap agglutinated cells during centrifugation.

• Procedure: RBCs or plasma are added to microtubes on plastic cards, incubated, and centrifuged.

• Interpretation:

  • Positive ($4+$): Large agglutinates are trapped at the very top of the gel.

  • Negative ($0$): Non-agglutinated cells travel freely to the bottom of the microtube.

Solid-Phase Red Cell Adherence (SPRCA) Technology

• Principle: Microplate wells are coated with an immobilized reagent (antigens or antibodies).

• Interpretation:

  • Positive: Cells adhere to the sides and bottom of the wells, forming a diffused layer.

  • Negative: Cells do not adhere and settle into a concentrated button at the bottom of the well.